EyePoint Pharmaceuticals Q2 2022 Earnings Report
Key Takeaways
EyePoint Pharmaceuticals reported a net product revenue of $11.3 million in Q2 2022, a 30% increase from Q2 2021. The company's total net revenue was $11.6 million compared to $9.0 million for the quarter ended June 30, 2021.
First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD).
Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting.
Announced in conjunction with OcuMension Therapeutics, approval of New Drug Application by China’s National Medical Products Administration (NMPA) for YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Net product revenue of $11.3 million in Q2 2022; a 30% increase from Q2 2021.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Revenue by Segment
Forward Guidance
We expect the cash, cash equivalents and investments on hand on June 30, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income